ArticleChemical & biomedical imaging2026
Mitochondria-Targeted Au@Carbon Dot Nanoprobes for SERS Analysis of Drug-Induced Mitophagy.
Article in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitophagy is closely associated with various diseases. Precise monitoring of its dynamics and understanding its mechanisms are crucial for diagnosing and treating mitophagy-related diseases. This study developed a mitochondria-targeted (MT) surface-enhanced Raman scattering (SERS) nanoprobe to investigate the drug-induced mitophagy through unveiling the mitochondria-related metabolic profiling. The MT-SERS nanoprobe is consist of carbon dots coated with gold nanoparticles functionalized with triphenylphosphonium (Au@CDs-TPP) that exhibits exceptional SERS performance, low cytotoxicity, and mitochondria targeting specificity. Au@CDs-TPP is first used to monitor the classic mitophagy triggered by carbonyl cyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP), which demonstrates the diverse metabolic profiling related to mitochondria, like degradation in mitochondrial protein, DNA damage, decreased lipid and cytochrome c content, and increased carbohydrate consumption. We further evaluate the cellular response to anesthetic lidocaine, which can also induce mitophagy in HepG2 cells like FCCP. However, the molecular alterations in lidocaine-induced mitophagy fluctuated differentially compared to that in FCCP-induced mitophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.